Limited coverage criteria - eprosartan (ARB)

Last updated on March 17, 2025

 

Return to Special Authority drug list 

Generic name 

eprosartan, including in combination with hydrochlorothiazide

Strength & form

600 mg, 600 mg/12.5 mg tablet

Special Authority criteria

Approval period

Person identified as experiencing intractable cough or angioedema on angiotensin-converting enzyme inhibitor (ACE-I)

AND

Failure on optimal doses of, or intolerance to, ALL reference drugs: candesartan, losartan, telmisartan AND valsartan

Indefinite

Practitioner exemptions

  • None

Special notes

  • Individuals requiring a diuretic combination product must satisfy the same criteria
  • Eprosartan 300 mg and 400 mg dosages are not PharmaCare benefits

Special Authority request form(s)